Notícias e Atividades da Autobahn Therapeutics

Veja o organograma con seus 17 executivos principais

Biografias mais buscadas da Autobahn Therapeutics

• Kevin Finney, Chairman and Chief Executive Officer
• Philip Desouza, Director
• Scott Giacobello, Director

Criar um alerta
para seguir os movimentos de executivos da Autobahn Therapeutics.

Autobahn Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Autobahn Therapeutics

• Autobahn Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Autobahn Therapeutics
• Autobahn Therapeutics Presents New Preclinical Data at ACNP Annual Meeting Supporting Novel Restorative Neuroplasticity Mechanism of Elunetirom - Autobahn Therapeutics
• Autobahn Therapeutics to Participate in 2025 Jefferies London Healthcare Conference - Autobahn Therapeutics
• Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences - Autobahn Therapeutics
• Autobahn Therapeutics to Participate in Evercore’s Emerging Private Biotech Conference - Autobahn Therapeutics
• Autobahn Therapeutics to Participate in Jefferies Global Healthcare Conference - Autobahn Therapeutics
• Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting - Autobahn Therapeutics
• Autobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression - Autobahn Therapeutics
• Autobahn Therapeutics Announces FDA Clearance of IND Application for ABX-002 as an Adjunctive Treatment for Bipolar Depression - Autobahn Therapeutics
• Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences - Autobahn Therapeutics
• View more press releases Close

Redes sociais sobre Autobahn Therapeutics

• Autobahn Therapeutics na Wikipedia, Google News e Yahoo Finance
• Autobahn Therapeutics na LinkedIn, X (Twitter) e YouTube